Who Gets Hired and onto Which Teams
Bicara Therapeutics hires for a narrow but deep set of functions tied to that mission rather than spreading across the broad portfolio of a large pharmaceutical company. Headquartered in Boston with roughly 130 employees, the company skews toward the disciplines that move a single clinical asset through the pipeline and toward launch readiness. Regulatory affairs, GxP quality and quality management systems, medical affairs, clinical trial management, medical writing, market access, commercial operations, and program management form the core of who Bicara brings on. Business operations and business strategy rank among the most active hiring teams as of September 16, 2026, alongside biotech and life sciences, per Migrate Mate's live postings.
The experience level skews senior. Most open roles on Migrate Mate as of September 16, 2026 are manager level or above, and the company's own board postings on Zero G Talent reflect the same pattern. Bicara is building out its leadership bench and launch infrastructure simultaneously. Entry-level openings are limited, and the company's job portal directs candidates to check individual listings for stated experience requirements.
That senior skew does not close the door on earlier-career talent. In 2026, Bicara launched its first intern cohort, bringing on students and emerging professionals for a ten-week program. On LinkedIn, the company described introducing Bicara's very first intern cohort, with interns spending the summer diving deep into their work. The program establishes a pipeline, significant for a company whose hiring concentrates at the senior end. Candidates who do not see an immediate fit are encouraged to apply even when no role is listed; the company says it will be in touch when the right position becomes available. That openness suggests the recruiting team will hold relationships with candidates whose skills may not match a current opening but fit the culture.
The cultural expectations embedded in who gets hired trace to three core principles: patient-driven, highly adaptive, openly candid. Bicara says its pace is "dictated by scientific necessity and fueled by a bias for action," and that it "pivots fearlessly when the data demands it." The company is not looking for people who wait for instructions or protect their turf. It wants candidates who absorb new information quickly, communicate honestly upward and across teams, and take ownership of problems outside a job description. Leadership, the company says, "leads with the grace and good intent required to give and receive the feedback that makes us better," and the rationale behind decisions is shared openly so the team stays aligned. Bicara's career page puts it plainly: "At Bicara, your career will not be boxed into a narrow lane. We bring our world-class expertise to the table but check our egos at the door, breaking down silos to combine our strengths for the patient." That maps directly to a hiring pattern favoring candidates who cross functional boundaries, specifically a regulatory professional who understands the commercial implications of a filing timeline, or a marketing operations person who grasps the science behind the asset.
Geographically, most roles sit in Boston, where the company is headquartered, though about 40% of postings offer remote or hybrid work as of September 16, 2026. The Senior Medical Science Liaison role spans California and Washington, indicating that some positions are structured around regional coverage. Bicara is an equal opportunity employer and states it will not discriminate on the basis of age, color, disability, gender, national origin, race, religion, sexual orientation, or veteran status.
Bicara is hiring for versatility: narrow but deep, senior in experience, high in cultural bar, but the internship program and its open-application policy suggest that candidates with the right blend of scientific literacy, operational grit, and collaborative instinct can find a path in even when one is not immediately visible on the job board.
Pay Runs from $133,000 to $310,000
Bicara Therapeutics' compensation rests on a salary band spanning $133,000 to $310,000, with a median of $235,000 across 13 salaried roles. That band captures the full spectrum of the company's hiring range, from junior individual contributors to senior leadership, and gives candidates a single reference line. The range is wide enough that a mid-career biostatistician and a first-year associate can both fall within it, which means the band alone signals the ceiling and floor but not where a specific function lands. Role-level data fills that gap.
Zero G Talent's live postings provide the most granular picture of what Bicara pays for named roles:
| Role | Location | Salary Band (USD/year) |
|---|---|---|
| Senior Director, Competitive Intelligence and Product Planning (Oncology) | Boston | $281,000–$331,000 |
| Senior Director, Regulatory Affairs | Boston | $275,000–$315,000 |
| Senior Medical Science Liaison – West (CA, WA) | United States | $242,000–$289,000 |
| Director, Biostatistics | Boston | $236,000–$274,000 |
| Director, Marketing Operations | Boston | $235,000–$268,000 |
| Associate Director, Global Scientific Communications | Boston | $199,000–$236,000 |
Equity operates differently depending on where you sit. For the executive tier, the structure is explicitly weighted toward long-term equity incentives. CEO Claire Mazumdar's 2024 total compensation of $8.9 million — nearly double the prior year — was driven primarily by substantial option awards, Panabee reported. Panabee's reporting describes the structure as heavily weighted towards long-term equity incentives, aligning executive pay with the company's stock performance. Bicara ties a meaningful share of pay to the long-term trajectory of its stock — for a clinical-stage biotech, the payoff is linked to pipeline progress, particularly ficerafusp alfa advancing through its phase 2/3 FORTIFI-HN01 trial. For employees below the executive level, equity is likely part of the package given the company's stage and sector norms, though specific mechanics (grant size, vesting schedule, strike price) are not broken out. Candidates should expect equity to form a component of total compensation at most levels.
Indeed's aggregated listing data extends the picture downward. Earlier-career positions show bands as low as $105,000–$128,000 and $167,000–$197,000, while mid-tier roles cluster around $193,000–$226,000 and $200,000–$235,000. Bicara's compensation floor sits near $105,000 for the most junior openings and pushes past $330,000 for its most senior roles, a span that broadly aligns with the board band while offering more resolution at the lower end.
A candidate evaluating a Bicara offer needs to think in two dimensions: the cash salary band, which is transparent and role-specific, and the equity overlay, which is less visible but structurally significant. The median of $235,000 is a useful anchor — if a role falls below it, the equity package likely compensates; if it falls above, the cash signals seniority or a specialized function like regulatory affairs or competitive intelligence. The range accommodates different career stages, and the equity architecture suggests Bicara is building a team meant to stay and grow through its next clinical inflection points.
How the Hiring Process Works
Bicara Therapeutics moves fast. Glassdoor data collected as of 2026 puts the company's hiring process at roughly 7 days across all job titles — a timeline that reflects a small, clinical-stage organization headquartered in Boston trying to fill roles at any given time. Candidates who match the profile Bicara is chasing can move from application to offer quickly; the company screens out mismatched applicants just as efficiently.
Candidates submit materials through Bicara's careers page, and the company is explicit about one rule: all formal communication regarding job opportunities comes exclusively from an @bicara.com email address. Bicara warns candidates who receive messages from any other domain to treat them as fraudulent. For candidates whose ideal role is not currently listed, a direct route exists, so send a resume and a brief cover letter to [email protected]. The company says it encourages people from all backgrounds to apply.
What happens after a candidate applies is less documented than most applicants would want. Third-party review platforms carry very little signal. GetWorkSignals notes there are not enough public notes on the evaluation process to build a reliable picture, and Quaerent reports zero candidate reviews, far short of the five needed to generate a company score. Candidates should not expect a detailed breakdown of interview rounds, take-home assignments, or panel formats from public sources. What Bicara makes visible are its stated values: Patient Driven, Highly Adaptive, and Openly Candid. These are not decorative slogans. They appear to function as the informal screening criteria that shape how interviewers evaluate candidates. A candidate who cannot demonstrate adaptability under the conditions of clinical-stage biotech will struggle to signal fit.
The first moments of an interview carry disproportionate weight. Research shows that interviewers form impressions about personality and intelligence within the first 30 seconds of an encounter. The practical implication for Bicara applicants is that the initial impression, how a candidate presents readiness for the specific role, matters more than a polished later narrative. The same source advises that a candidate's primary job in the interview is to demonstrate they are perfectly suited for the role, which aligns with Bicara's efficiency-driven timeline.
Two structural factors shape who gets through the process. The first is the company's small size and focused mandate. As a clinical-stage biotech developing bifunctional antibodies, Bicara needs specialists who can operate with limited overhead, which means generalists or candidates without relevant biotech experience face a steeper climb. The second is the ghost rate, or the share of contacted or interviewed candidates who never hear back. While Bicara's specific ghost rate is not publicly available, reaching a final interview stage does not guarantee an outcome. Candidates who advance should expect rapid communication and should not assume silence is a delay, as in a 7-day process, silence often signals a rejection.
There is no verified, detailed account of Bicara's interview stages, question formats, or scoring rubrics available through third-party aggregators. The most useful preparation is to internalize the company's three stated values, demonstrate concrete relevance to the specific role posted, and ensure all correspondence comes through the @bicara.com channel.
Where the Work Happens
Bicara Therapeutics runs its operations out of the greater Boston area, where the company has been rapidly expanding its physical presence since its debut as a spinout from Scorpion Therapeutics. As of mid-2025, Bicara doubled its footprint — a signal that lab and office capacity has scaled sharply in a short window, consistent with a clinical-stage biotechnology operation moving programs forward at pace.
The Boston base anchors the bulk of hiring. Most roles on the board, including Senior Director, Competitive Intelligence and Product Planning; Senior Director, Regulatory Affairs; Director, Biostatistics; Director, Marketing Operations; and Associate Director, Global Scientific Communications, are listed as Boston-based. A biotech company that has doubled its physical footprint needs researchers, regulatory specialists, and operational staff who can work on-site in a lab environment. Boston is a major cluster of life sciences talent in the country.
That institutional connection places Bicara inside the local infrastructure Massachusetts has built around life sciences, from shared lab space to workforce development pipelines. The award also points to a programmatic focus on health equity that shapes how the company thinks about its research and community-facing work, even if it does not break down which programs that funding supports.
Not every role is tied to a physical bench. The board lists a Senior Medical Science Liaison, West (covering California and Washington), as a remote or field-based position, which reflects a pattern in which headquarters and labs anchor the science while commercial-facing roles like medical science liaisons operate across geographies to maintain relationships with key opinion leaders and healthcare systems. That single West Coast posting suggests Bicara is building a commercial infrastructure alongside its research operations, even at this relatively early stage of its lifecycle.
The doubled footprint enables a fuller pipeline workflow, the kind of lab capacity that lets a clinical-stage company move from discovery through preclinical and early clinical work without bottlenecks on bench space or specialized equipment. For a spinout that has been hiring across these functions, that expanded physical capacity is the backbone supporting every other function the company is building out. The Boston location gives Bicara access to academic medical networks, contract research organizations, and the talent pool a clinical-stage biotech needs to move programs at the speed its funding implies.
The research digest does not break down lab configurations, square footage, or campus layout at each site. Bicara doubled its footprint in a compressed period and received state-level recognition. The company is building toward a sustained operational presence, not a temporary one.
Who Thrives Here
Bicara Therapeutics' hiring record points toward a specific kind of professional: someone who operates comfortably inside a hybrid of scientific rigor and commercial discipline. The functional mix the company recruits across, quality, marketing, bio/chem, finance, and research, is not incidental. It signals an organization where silos are thin and where the people who last tend to be those who can translate between domains rather than retreat into them. A Director of Marketing Operations posting and a Senior Director of Regulatory Affairs posting sitting in the same hiring cycle tells you something about Bicara's operating assumption: every function touches the product's path to market, and the people who thrive are those who understand that intersection.
The seniority profile reinforces this reading. The company is not staffing for entry-level volume; it is building layers of experienced specialists whose compensation reflects deep domain expertise. The highest-compensated roles on the board demand deep domain expertise paired with leadership scope, and the company's job descriptions consistently pair senior titles with oncology-specific or regulatory-specific requirements, which means a generalist career arc is less likely to land here than a track record of focused, domain-deep contribution.
The geographic concentration, Boston for the majority of roles, with a Senior Medical Science Liaison covering the West Coast (CA, WA), adds another layer. The company's heavy presence there suggests a preference for candidates embedded in or willing to relocate to that ecosystem. The single West Coast posting indicates that field-facing science positions are distributed strategically rather than broadly, which means Bicara values targeted presence over wide geographic spread. Candidates who thrive here are likely those who are either already located in or committed to the Boston life sciences corridor, or who hold the kind of specialized field role that justifies a regional assignment.
What the available employee accounts add is limited but instructive. Bicara Therapeutics has roughly one review on Glassdoor as of the latest available data, a thin sample that should temper any broad claims about culture. Even a single review, read alongside the job mix, reinforces the picture of a company that values specialized expertise over generalist versatility. The absence of many reviews means what Bicara posts and how it structures its teams tells you more about its culture than employee testimony would. Candidates should read the job postings themselves as the primary cultural document: they reveal that Bicara expects people who can own complex, technical work streams and who are comfortable operating in an environment where the distance between a scientific question and a commercial decision is short.
The cross-functional demand also carries a practical implication for who will find the environment energizing rather than draining. Someone who prefers clearly bounded, self-contained work, where their function's output is the final product, may struggle in a structure where regulatory strategy, marketing operations, and scientific communications all converge on the same asset. The people who tend to last at Bicara draw energy from that convergence, seeing the commercial and the scientific as inseparable halves of a single mission, and can communicate across those divides without losing technical credibility.
Bicara's hiring pattern tells a simple story: the molecule doesn't care who wrote the filing or who designed the trial, it only moves forward when the people building around it can see past the boundaries of their own functions. The company pays for that vision, and it screens for it, too.
Working in frontier tech? Zero G Talent tracks the openings: see every open Bicara Therapeutics role, browse frontier tech jobs, the companies hiring, and the people building the field.